KEVIN SUMMERS: Open Payments
NPI 1477103851 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$533 in 12 payments from 9 companies in 2025. Trend: 2023 $0 · 2024 $0 · 2025 $533
Food & beverage: $533
| Company | Payments | Amount |
|---|---|---|
| TG Therapeutics, Inc. | 2 | $216 |
| AstraZeneca Pharmaceuticals LP | 2 | $130 |
| Janssen Biotech, Inc. | 2 | $46 |
| Alnylam Pharmaceuticals Inc. | 1 | $34 |
| ARGENX US, INC. | 1 | $24 |
| Alexion Pharmaceuticals, Inc. | 1 | $23 |
| Biogen, Inc. | 1 | $23 |
| Genentech USA, Inc. | 1 | $20 |
| GlaxoSmithKline, LLC. | 1 | $18 |
Products named: BRIUMVI, TEZSPIRE, TREMFYA, ONPATTRO, SAPHNELO, VYVGART HYTRULO, ULTOMIRIS, TYSABRI.
Industry payments across TX — which companies pay providers there.
